Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.

Launched by ART FERTILITY CLINICS LLC · Aug 4, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring the best timing for transferring a specific type of embryo, called a euploid day 6 blastocyst, in women undergoing fertility treatments. Researchers want to find out if transferring this embryo on the 6th day or the 7th day of progesterone treatment leads to better outcomes, such as clinical pregnancy rates, live births, and miscarriage rates. This study is important because it focuses on embryos that are genetically normal, which may help to understand how timing affects the chances of a successful pregnancy.

To participate in this trial, women must be between 18 and 43 years old and must have at least one healthy, cryopreserved day 6 blastocyst of good quality. They should also have a specific type of uterine lining appearance on the day they start progesterone treatment. Women with certain uterine conditions or known allergies to the medications used in the trial cannot participate. If eligible, participants can expect to be randomly assigned to either the 6th or 7th day transfer and will help advance our understanding of fertility treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women aged 18 years to 43 years.
• • Having at least 1 euploid cryopreserved day 6 blastocyst of at least Grade BB quality.
• • Endometrial trilaminar appearance on the day of progesterone start
• Exclusion Criteria:
• • Uterine abnormality
• • Hydrosalpinx
• • Asherman syndrome
• • Any known contraindications or allergy to oral estradiol or progesterone.
• * Intention to treat : exclusion factors :
• • 1. Spontaneous ovulation HRT cycle
• • 2. Discontinuation of HRT medication